These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22329602)

  • 1. Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
    Daval SB; Valant C; Bonnet D; Kellenberger E; Hibert M; Galzi JL; Ilien B
    J Med Chem; 2012 Mar; 55(5):2125-43. PubMed ID: 22329602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
    Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
    Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor.
    Tahtaoui C; Parrot I; Klotz P; Guillier F; Galzi JL; Hibert M; Ilien B
    J Med Chem; 2004 Aug; 47(17):4300-15. PubMed ID: 15294002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
    Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
    Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
    Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
    Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
    Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies.
    Tahtaoui C; Guillier F; Klotz P; Galzi JL; Hibert M; Ilien B
    J Med Chem; 2005 Dec; 48(24):7847-59. PubMed ID: 16302823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.
    Avlani VA; Langmead CJ; Guida E; Wood MD; Tehan BG; Herdon HJ; Watson JM; Sexton PM; Christopoulos A
    Mol Pharmacol; 2010 Jul; 78(1):94-104. PubMed ID: 20413650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FRET-based detection of M1 muscarinic acetylcholine receptor activation by orthosteric and allosteric agonists.
    Markovic D; Holdich J; Al-Sabah S; Mistry R; Krasel C; Mahaut-Smith MP; Challiss RA
    PLoS One; 2012; 7(1):e29946. PubMed ID: 22272263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fluorescence anisotropy assay for the muscarinic M1 G-protein-coupled receptor.
    Huwiler KG; De Rosier T; Hanson B; Vogel KW
    Assay Drug Dev Technol; 2010 Jun; 8(3):356-66. PubMed ID: 20233092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.
    Thomas RL; Langmead CJ; Wood MD; Challiss RA
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1086-95. PubMed ID: 19767446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.
    Davis CN; Bradley SR; Schiffer HH; Friberg M; Koch K; Tolf BR; Bonhaus DW; Lameh J
    BMC Pharmacol; 2009 Dec; 9():14. PubMed ID: 19951444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
    Fruchart-Gaillard C; Mourier G; Marquer C; Ménez A; Servent D
    Mol Pharmacol; 2006 May; 69(5):1641-51. PubMed ID: 16439611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
    De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
    J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.
    Digby GJ; Utley TJ; Lamsal A; Sevel C; Sheffler DJ; Lebois EP; Bridges TM; Wood MR; Niswender CM; Lindsley CW; Conn PJ
    ACS Chem Neurosci; 2012 Dec; 3(12):1025-36. PubMed ID: 23259038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel BQCA- and TBPB-Derived M
    Schramm S; Agnetta L; Bermudez M; Gerwe H; Irmen M; Holze J; Littmann T; Wolber G; Tränkle C; Decker M
    ChemMedChem; 2019 Jul; 14(14):1349-1358. PubMed ID: 31166078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors.
    Ziegler N; Bätz J; Zabel U; Lohse MJ; Hoffmann C
    Bioorg Med Chem; 2011 Feb; 19(3):1048-54. PubMed ID: 20716489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.
    Spalding TA; Ma JN; Ott TR; Friberg M; Bajpai A; Bradley SR; Davis RE; Brann MR; Burstein ES
    Mol Pharmacol; 2006 Dec; 70(6):1974-83. PubMed ID: 16959945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.